Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance.

作者: Gordon L Grado , Thayne R Larson , Carrie S Balch , Mary M Grado , Joseph M Collins

DOI: 10.1016/S0360-3016(98)00209-0

关键词: Survival analysisProstate cancerBrachytherapyProstateProstate-specific antigenActuarial scienceRadiation therapyMedicineExternal beam radiotherapyRetrospective cohort study

摘要: Abstract Purpose: To evaluate the effectiveness and safety of interactive transperineal brachytherapy under biplane ultrasound fluoroscopic guidance in patients with localized prostate cancer. Methods Materials: Brachytherapy using 125 I or 103 Pd radioactive seeds either alone combination adjunctive external beam radiotherapy (XRT) was administered to 490 at a single institution. Post-treatment follow-up included clinical assessment disease status, assays serum prostate-specific antigen (PSA) levels documentation treatment-related symptoms complications. Results: Actuarial disease-free survival 5 yr 79% (95% CI, 71–85%), 5-yr actuarial rate local control 98% 94–99%). PSA nadir pretreatment level were found be significant predictors survival. In 1.0 ng/ml. well tolerated few post-treatment Conclusion: A broad range cancer can benefit from minimal morbidity. below 0.5 ng/ml provides useful prognostic indicator favorable long-term outcome.

参考文章(44)
Irving D. Kaplan, Richard S. Cox, Malcolm A. Bagshaw, Prostate Specific Antigen after External Beam Radiotherapy for Prostatic Cancer: Followup Journal of Urology. ,vol. 149, pp. 519- 522 ,(1993) , 10.1016/S0022-5347(17)36133-5
A.L. Zietman, J.J. Coen, W.U. Shipley, C.G. Willett, J.T. Efird, Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome The Journal of Urology. ,vol. 151, pp. 640- 645 ,(1994) , 10.1016/S0022-5347(17)35036-X
Timothy E. Weyrich, Stanley J. Kandzari, Pushpa R. Jain, Iodine 125 seed implants for prostatic carcinoma Urology. ,vol. 41, pp. 122- 126 ,(1993) , 10.1016/0090-4295(93)90160-C
T M Pisansky, S S Cha, J D Earle, E D Durr, T F Kozelsky, H S Wieand, J E Oesterling, Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. Journal of Clinical Oncology. ,vol. 11, pp. 2158- 2166 ,(1993) , 10.1200/JCO.1993.11.11.2158
B Chauvet, C Félix-Faure, N Lupsascka, J Fijuth, Y Brewer, J L Davin, S Kirscher, F Reboul, Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy. Journal of Clinical Oncology. ,vol. 12, pp. 1402- 1407 ,(1994) , 10.1200/JCO.1994.12.7.1402
David C. Utz, Pathologic Differentiation and Prognosis of Prostatic Carcinoma JAMA: The Journal of the American Medical Association. ,vol. 209, pp. 1701- 1703 ,(1969) , 10.1001/JAMA.1969.03160240057016
HAAKON RAGDE, JOHN C. BLASKO, DOUGLAS SCHUMACHER, PETER D. GRIMM, DAVID L. CUNNINGHAM, JOHN SYLVESTER, TIMOTHY P. MATE, Use of Transrectal Ultrasound in Transperineal 125Iodine Seeding for Prostate Cancer: Methodology Journal of Endourology. ,vol. 3, pp. 209- 218 ,(1989) , 10.1089/END.1989.3.209